Conmed (CNMD) reported $373.2 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 7.9%. EPS of $1.43 for the same period compares to $1.34 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $366.22 million, representing a surprise of +1.91%. The company delivered an EPS surprise of +8.61%, with the consensus EPS estimate being $1.32.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Conmed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- Domestic: $206.2 million compared to the $205.31 million average estimate based on two analysts. The reported number represents a change of +1.4% year over year.
- Geographic Revenue- International: $167 million versus the two-analyst average estimate of $160.92 million. The reported number represents a year-over-year change of +17.1%.
- Net Sales- Orthopedic Surgery: $157.4 million versus $147.41 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +13.2% change.
- Net Sales- Capital Products: $52.6 million versus $53.13 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.2% change.
- Net Sales- Single-use Products: $320.6 million compared to the $313.1 million average estimate based on two analysts. The reported number represents a change of +7.8% year over year.
- Net Sales- General Surgery: $215.8 million versus $218.82 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.3% change.
View all Key Company Metrics for Conmed here>>>
Shares of Conmed have returned -3.8% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CONMED Corporation (CNMD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
